UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2015
Commission File Number: 001-33036
Mindray
Medical International Limited
Mindray Building, Keji 12th Road South,
Hi-tech Industrial Park, Nanshan,
Shenzhen 518057
Peoples Republic of China
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨
No þ
If Yes is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): N/A
TABLE
OF CONTENTS
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
Mindray Medical International Limited |
|
|
By: |
|
/s/ Alex Lung |
|
|
Name: Alex Lung |
|
|
Title: Chief Financial Officer |
Date: July 7, 2015
3
Exhibit 99.1
Mindray Medical to Acquire the Remaining
Stake in Wuhan Dragonbio
SHENZHEN, China, July 7, 2015 -- Mindray
Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices
worldwide, announced today a definitive agreement to acquire the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd.
("Dragonbio") for approximately US$72.6 million.
Dragonbio is a domestic medical orthopedic-product
provider that specializes in trauma, spine, joint and other surgical products. Prior to today’s announcement, Mindray already
has a controlling stake of Dragonbio, which was acquired in 2012. The transaction will be funded through Mindray's existing cash
reserves and is expected to close in July. Mindray expects the deal to have non-material impact on its 2015 financial results.
"Since we acquired a majority stake
of Dragonbio in 2012, the integration has been well on track," said Mr. Minghe Cheng, Mindray's Co-Chief Executive Officer and
Chief Strategic Officer. "We are optimistic about the prospects of the orthopedic consumable market in China and have therefore
decided to make Dragonbio our wholly owned subsidiary. The transaction is expected to help us manage and expand the business more
efficiently and effectively through our strong capital position, large-scale operational experience and worldwide presence."
Cautionary Note Regarding Forward-Looking
Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the Private securities Litigation Reform Act of 1995. Statements
that are not historical facts, including without limitation, the anticipated transaction and timing, our expectation about the
non-material impact of the deal on our 2015 financial results, statements that we are optimistic about the prospects of the orthopedic
consumable market in China, that the transaction is expected to help us manage and expand the business more efficiently and effectively
through our strong capital position, large-scale operational experience and worldwide presence and other statements about Mindray’s
belief and expectations are "forward-looking" statements. These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates" and similar statements. Mindray may also make written or oral forward-looking statements
in its periodic reports to the U.S. Securities and Exchange Commission on forms 20-F and 6-K, in its annual report to shareholders,
in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties.
Readers are cautioned that these forward-looking statements are only predictions. Forward-looking statements involve inherent
risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. A number of
important factors including without limitation, competitive, pricing and other conditions in China and our international markets
and our ability to effectively address or respond those conditions; our ability effectively attract and retain our key employees;
the growth and expected growth of the medical device market in China and internationally; applicable government policies and regulations;
our ability to satisfy the requirements imposed by relevant regulatory bodies; market acceptance of our products; our expectations
regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects
of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect
our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes
with our customers and suppliers; and general economic and business conditions in the countries in which we operate, could cause
actual results to differ materially from those contained in any forward-looking statement. For a discussion of other important
factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors"
beginning on page 6 of our annual report on Form 20-F which was filed on April 16, 2015. Potential risks and uncertainties include,
but are not limited to, the transaction may not close when expected or at all, the transaction may have more or less impact on
the company’s 2015 financial results than expected, the anticipated transaction benefits may not be realized and such other
risks outlined in Mindray's filings with the U.S. Securities and Exchange Commission, including its registration statements
on Form F-1, F-3 and 20-F, in each case as amended. Any projections in this release are based on limited information currently
available to us, which is subject to change. Although such projections and the factors influencing them will likely change, Mindray
does not necessarily undertake any obligation to update any forward-looking statements, except as required under applicable law.
Such forward-looking statements speak only as of the date of this release.
About Mindray
We are a leading developer, manufacturer and marketer of medical
devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and
multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply
through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring
and life support, in-vitro diagnostics, and medical imaging systems. For more information, please visit http://ir.mindray.com.
For investor and media inquiries, please
contact:
In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com
In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com
Montage Resources (NYSE:MR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Montage Resources (NYSE:MR)
Historical Stock Chart
From Apr 2023 to Apr 2024